Carregant...
Cost burden of diffuse large B-cell lymphoma
INTRODUCTION: Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma and is a clinically heterogenous disease. Treatment pathways for DLBCL are diverse and integrate established and novel therapies. AREAS COVERED: We review the cost burden of DLBCL and cost-effectiveness of DL...
Guardat en:
| Publicat a: | Expert Rev Pharmacoecon Outcomes Res |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6930962/ https://ncbi.nlm.nih.gov/pubmed/31623476 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14737167.2019.1680288 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|